Brief: Simcere Pharmaceutical Revises Maximum Aggregate Price Under Existing Share Repurchase To RMB1 Bln
March 20 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* SHARE REPURCHASE
* RESOLVED TO REVISE MAXIMUM AGGREGATE PRICE UNDER EXISTING
SHARE
REPURCHASE PROPOSAL FROM RMB500 MILLION TO RMB1 BILLION
* REVISED SHARE REPURCHASE PROPOSAL SHALL BE EFFECTIVE FROM
MARCH
20
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660